^
    Apply
    Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors (NCT05181865)
    Phase 1/2
    Flame Biosciences
    Withdrawn
    Last update posted :
    02/07/2022
    Initiation :
    01/01/2022
    Primary completion :
    01/18/2022
    Completion :
    01/18/2022
    CLDN18
    |
    CLDN1 positive
    |
    NBL-015
    Evaluation of the Safety and Efficacy of NBL-015 in Patients With Advanced Solid Tumors (NBL-015-CSP-001) (NCT05153096)
    Phase 1
    NovaRock Biotherapeutics, Ltd
    Not yet recruiting
    Last update posted :
    12/31/2021
    Initiation :
    04/01/2022
    Primary completion :
    12/01/2025
    Completion :
    12/01/2025
    CLDN18
    |
    NBL-015